USL261

DRUG4 trials

Sponsors

UCB Biopharma S.P.R.L.

Conditions

Epilepsy

Phase 3

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

TerminatedNCT01390220

UCB Biopharma S.P.R.L.Epilepsy

Start: 2011-06-30End: 2017-03-31Updated: 2019-10-10

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

TerminatedNCT01529034

UCB Biopharma S.P.R.L.Epilepsy

Start: 2012-07-31Updated: 2023-01-20

Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU

CompletedNCT01999777

UCB Biopharma S.P.R.L.Epilepsy

Start: 2013-11-30End: 2015-08-31Updated: 2019-10-10

A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

TerminatedNCT02161185

UCB Biopharma S.P.R.L.Epilepsy

Start: 2014-05-31End: 2015-05-31Updated: 2019-10-10

Related Papers

Return to full baseline functionality after repeated intermittent use of midazolam nasal spray in patients with seizure clusters: Post hoc analysis of an open-label extension trial.

2023-10-292 citations

Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: Results of a phase 3, open-label extension trial

Epilepsy & Behavior2022-11-1813 citations

Safety and efficacy of midazolam nasal spray for the treatment of intermittent bouts of increased seizure activity in the epilepsy monitoring unit: A double‐blind, randomized, placebo‐controlled trial

Epilepsia2020-11-0115 citations

Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: An open-label extension trial.

2019-07-2935 citations

Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial.

2019-05-2976 citations